Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Vaccinia virus, no longer required for immunization against smallpox, now serves as a unique vector for expressing genes within the cytoplasm of mammalian cells. As a research tool, recombinant vaccinia viruses are used to synthesize and analyze the structure-function relationships of proteins, determine the targets of humoral and cell-mediated immunity, and investigate the types of immune response needed for protection against specific infectious diseases and cancer. The vaccine potential of recombinant vaccinia virus has been realized in the form of an effective oral wild-life rabies vaccine, although no product for humans has been licensed. A genetically altered vaccinia virus that is unable to replicate in mammalian cells and produces diminished cytopathic effects retains the capacity for high-level gene expression and immunogenicity while promising exceptional safety for laboratory workers and potential vaccine recipients.
Moss
B
B
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0445, USA.
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control; D000818:Animals; D000917:Antibody Formation; D002478:Cells, Cultured; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D007111:Immunity, Cellular; D008322:Mammals; D011212:Poxviridae / Q000235:genetics* / Q000276:immunology; D011213:Poxviridae Infections / Q000276:immunology / Q000517:prevention & control; D012449:Safety; D012899:Smallpox / Q000276:immunology* / Q000517:prevention & control; D014162:Transfection / Q000379:methods*; D014611:Vaccination; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology*; D014764:Viral Proteins / Q000096:biosynthesis
D016915:AIDS Vaccines; D014614:Vaccines, Synthetic; D014764:Viral Proteins